Search Orphan Drug Designations and Approvals
-
| Generic Name: | an investigational chimeric antigen receptor (CAR) T-cell product that consists of autologous T cells that have been transduced with a genetically engineered replication-incompetent, third-generation, self-inactivating lentiviral vector encoding a G protein-coupled receptor class C, group 5, member D (GPRC5D)-specific CAR |
|---|---|
| Date Designated: | 06/21/2023 |
| Orphan Designation: | Treatment of multiple myeloma |
| Orphan Designation Status: | Designated |
| FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
| Sponsor: |
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company 400 Dexter Avenue N, Suite 1200 Seattle, Washington 98109 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







